Get the Stockscreener App
9.36
0.43%
-0.04
Pre-market:
9.45
0.09
+0.96%
Prothena Corporation Plc stock is traded at $9.36, with a volume of 553.44K.
It is down -0.43% in the last 24 hours and up +6.61% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$9.40
Open:
$9.09
24h Volume:
553.44K
Relative Volume:
0.99
Market Cap:
$503.85M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-9.36
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+4.35%
1M Performance:
+6.61%
6M Performance:
+11.56%
1Y Performance:
-34.68%
1-Day Range:
$8.95
$9.615
1-Week Range:
$8.48
$9.615
52-Week Range:
$4.32
$15.63
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
9.36 | 506.00M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Zacks Investment Research
Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Prothena Corporation plc (PRTA) Stock Analysis: Navigating a 137% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Prothena Announces $100 Million Share Repurchase Program - TipRanks
Prothena authorizes $100 million share buyback program - Investing.com
Prothena Corporation plc announces an Equity Buyback for $100 million worth of its shares. - marketscreener.com
Prothena (NASDAQ: PRTA) okays $100M share buyback through 2026 - Stock Titan
Prothena Approves $100 Million Share Buyback Authorization - marketscreener.com
Prothena stock jumps on $100M share buyback authorization - Investing.com UK
Prothena Corporation plc (NASDAQ: PRTA) clears shelf to sell up to $200M in shares - Stock Titan
Prothena Announces up to $100 Million Share Repurchase Plan - Bluefield Daily Telegraph
PROTHENA CORP PUBLIC LTD CO SEC 10-K Report - TradingView
Prothena Corporation plc authorizes a Buyback Plan. - marketscreener.com
Behavioral Patterns of PRTA and Institutional Flows - Stock Traders Daily
FY2026 EPS Estimates for Prothena Boosted by HC Wainwright - MarketBeat
Royal Bank Of Canada Increases Prothena (NASDAQ:PRTA) Price Target to $12.00 - Defense World
RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12. - GuruFocus
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz
Prothena (NASDAQ:PRTA) Price Target Raised to $12.00 - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Q4 2025 Earnings Call Transcript - Insider Monkey
Prothena Corporation plc Q4 2025 Earnings Call Summary - Yahoo Finance
Prothena Corp PLC (PRTA) Q4 2025 Earnings Call Highlights: Strat - GuruFocus
Prothena Q4 Earnings Call Highlights - MarketBeat
Can Prothena Corporation plc be recession proofTrade Exit Summary & Growth Focused Stock Reports - mfd.ru
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Prothena (PRTA) Projects Financial Outlook and Clinical Milestones - GuruFocus
Prothena Corporation plc announced that the company has the potential to receive up to $105 million in cumulative clinical milestone payments by the end of 2026. - Bitget
Prothena (NASDAQ:PRTA) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights - The Joplin Globe
Exploring Prothena Corp's Earnings Expectations - Benzinga
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? - Finviz
(PRTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Will Prothena Corporation plc stock remain a Wall Street favoriteQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - mfd.ru
Prothena Corporation plc (PRTA) Stock Analysis: Exploring a 129.76% Potential Upside in Biotechnology - DirectorsTalk Interviews
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - pharmiweb.com
Prothena (PRTA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is Prothena Corporation plc stock affected by interest rate hikes2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Will Prothena Corporation plc benefit from rising consumer demandJuly 2025 Retail & Stepwise Swing Trade Plans - mfd.ru
Aug Levels: Will Prothena Corporation plc benefit from rising consumer demandMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Volatility Watch: How do insiders feel about Prothena Corporation plcWeekly Stock Report & Smart Money Movement Tracker - baoquankhu1.vn
Prothena Corporation plc (NASDAQ:PRTA) Given Average Rating of "Hold" by Analysts - MarketBeat
How (PRTA) Movements Inform Risk Allocation Models - Stock Traders Daily
Prothena Corporation plc $PRTA Shares Sold by Federated Hermes Inc. - MarketBeat
Prothena Corporation plc (PRTA) Stock Analysis: Exploring a Potential 124% Upside in Biotech Innovations - DirectorsTalk Interviews
Prothena (NASDAQ:PRTA) Share Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Can Calidi Biotherapeutics Inc reach resistance levels soonWeekly Stock Summary & Community Trade Idea Sharing - baoquankhu1.vn
Trading Systems Reacting to (PRTA) Volatility - Stock Traders Daily
Prothena Corporation Plc (PRTA) Stock Analysis: Evaluating A Potential 96.65% Upside - DirectorsTalk Interviews
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy - Yahoo Finance
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):